We believe that leptin therapy in these selected individuals may address these abnormalities and improving hepatic de novo lipogenesis with a readout of improved fasting hypertriglyceridemia and liver steatosis (potentially hepatocyte injury and inflammation). The gene discussed is LEP; the disease is fatty liver disease.